Insider Buying: Ernest Mario Buys 10,000 Shares of Chimerix Stock (CMRX)
Chimerix (NASDAQ:CMRX) Director Ernest Mario purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 27th. The shares were purchased at an average price of $14.22 per share, for a total transaction of $142,200.00. Following the completion of the transaction, the director now directly owns 68,451 shares of the company’s stock, valued at approximately $973,373. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on CMRX shares. Analysts at Stifel Nicolaus initiated coverage on shares of Chimerix in a research note on Thursday, March 13th. They set a “buy” rating and a $34.00 price target on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Chimerix in a research note on Wednesday, March 12th. They now have a $34.00 price target on the stock.
Chimerix (NASDAQ:CMRX) traded up 10.19% on Wednesday, hitting $19.68. 406,915 shares of the company’s stock traded hands. Chimerix has a 52-week low of $12.96 and a 52-week high of $27.69. The stock has a 50-day moving average of $18. and a 200-day moving average of $18.48. The company’s market cap is $530.7 million.
Chimerix (NASDAQ:CMRX) last announced its earnings results on Friday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.36) by $0.03. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.85 million. During the same quarter last year, the company posted ($22.58) earnings per share. On average, analysts predict that Chimerix will post $-1.83 earnings per share for the current fiscal year.
Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.